Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innate Pharma SA ( (FR:IPH) ) just unveiled an update.
On June 17, 2025, Innate Pharma announced its participation in upcoming virtual investor conferences, including the H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference on June 24, 2025, and Wolfe Research Virtual Biotech Day on June 26, 2025. This participation underscores Innate Pharma’s active engagement in the biotech industry and its commitment to advancing its innovative cancer immunotherapy pipeline, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to accelerate research and development.
Average Trading Volume: 108,015
Technical Sentiment Signal: Strong Sell
Current Market Cap: €153M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.